Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial

Clinical Research in Cardiology

Volumn 107, Issue 12, 2018, Pages 1192-1195

  Ferreira, João Pedro ^a,b   Barros, António ^b   Pitt, Bertram ^c   Montalescot, Gilles ^d   de Sa, Esteban Lopez ^e   Hamm, Christian W ^f   Flather, Marcus ^g   Verheugt, Freek ^h   Shi, Harry ⁱ   Leite Moreira, Adelino ^b   Vincent, John ⁱ   Rossignol, Patrick ^a   Zannad, Faiez ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b University of Porto   (Portugal)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f KERCKHOFF HEART CENTER   (Germany)

^g UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^h ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

ⁱ PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; EPLERENONE; GALECTIN 3; BIOLOGICAL MARKER; COLLAGEN; MINERALOCORTICOID ANTAGONIST;

ATRIAL FIBRILLATION; COLLAGEN SYNTHESIS; CONGESTIVE CARDIOMYOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; LETTER; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCAR FORMATION; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC DYSFUNCTION; FIBROSIS; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BIOMARKERS; COLLAGEN; EPLERENONE; FIBROSIS; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ST ELEVATION MYOCARDIAL INFARCTION;

EID: 85053922625     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-018-1373-5     Document Type: Letter

References (25)

1. Khoury S, Carmon S, Margolis G, Keren G, Shacham Y (2017) Incidence and outcomes of early left ventricular thrombus following ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Clin Res Cardiol 106(9):695–701
2. Ferreira JP, Duarte K, Montalescot G, Pitt B, de Sa EL, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Rossignol P, Vincent J, Zannad F (2017) Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. Clin Res Cardiol 107(1):49–59
3. Zannad F, Alla F, Dousset B, Perez A, Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investig Circ 102(22):2700–2706
4. Quilliot D, Alla F, Bohme P, Bruntz JF, Hammadi M, Dousset B, Ziegler O, Zannad F (2005) Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int J Obes (Lond) 29(11):1321–1328
5. Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, Vincent J, Pitt B, Zannad F (2009) Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119(18):2471–2479
6. Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, Shi H, Turgonyi E, Orri M, Vincent J, Zannad F (2014) Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study. In: Eur Heart J, Published on behalf of the European Society of Cardiology The Author 2014. For permissions please email: journals.permissions@oup.com.: England, vol 35, pp 2295–2302
7. Beygui F, Cayla G, Roule V, Roubille F, Delarche N, Silvain J, Van Belle E, Belle L, Galinier M, Motreff P, Cornillet L, Collet JP, Furber A, Goldstein P, Ecollan P, Legallois D, Lebon A, Rousseau H, Machecourt J, Zannad F, Vicaut E, Montalescot G (2016) Early Aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial. J Am Coll Cardiol 67(16):1917–1927
8. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J (2001) The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 15(1):79–87
9. Ferreira JP, Mentz RJ, Pizard A, Pitt B, Zannad F (2017) Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? Eur J Heart Fail 19(8):974–986
10. Lopez B, Gonzalez A, Ravassa S, Beaumont J, Moreno MU, San Jose G, Querejeta R, Diez J (2015) Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol 65(22):2449–2456
11. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M (2005) Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112(19):2940–2945
12. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, Pacher R, Grimm M, Pribill I, Eichler HG et al (1995) Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75(14):913–918
13. Condorelli G, Jotti GS, Pagiatakis C (2016) Fibroblast senescence as a therapeutic target of myocardial fibrosis: beyond spironolactone? J Am Coll Cardiol 67(17):2029–2031
14. Sun Y, Weber KT (2000) Infarct scar: a dynamic tissue. Cardiovasc Res 46(2):250–256
15. Gyongyosi M, Winkler J, Ramos I, Do QT, Firat H, McDonald K, Gonzalez A, Thum T, Diez J, Jaisser F, Pizard A, Zannad F (2017) Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail 19(2):177–191
16. Ferreira JP, Machu JL, Girerd N, Jaisser F, Thum T, Butler J, Gonzalez A, Diez J, Heymans S, McDonald K, Gyongyosi M, Firat H, Rossignol P, Pizard A, Zannad F (2017) Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Fail 5(1):139–148
17. Heymans S, Gonzalez A, Pizard A, Papageorgiou AP, Lopez-Andres N, Jaisser F, Thum T, Zannad F, Diez J (2015) Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. Eur J Heart Fail 17(8):764–771
18. Uusimaa P, Risteli J, Niemela M, Lumme J, Ikaheimo M, Jounela A, Peuhkurinen K (1997) Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 96(8):2565–2572
19. Lopez B, Gonzalez A, Querejeta R, Larman M, Rabago G, Diez J (2014) Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 63(3):483–489
20. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M (2003) Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107(20):2559–2565
21. Arantxa G, Schelbert EB, Diez J, Butler J (2018) Myocardial interstitial fibrosis in heart failure. J Am Coll Cardiol 71(15):1696–1706
22. Lin YH, Chou CH, Wu XM, Chang YY, Hung CS, Chen YH, Tzeng YL, Wu VC, Ho YL, Hsieh FJ, Wu KD (2014) Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans. PLoS One 9(9):e95254
23. Azibani F, Benard L, Schlossarek S, Merval R, Tournoux F, Fazal L, Polidano E, Launay JM, Carrier L, Chatziantoniou C, Samuel JL, Delcayre C (2012) Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension 59(6):1179–1187
24. Lopez B, Gonzalez A, Querejeta R, Zubillaga E, Larman M, Diez J (2015) Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail 17(4):385–392
25. Sturgis LC, Cannon JG, Schreihofer DA, Brands MW (2009) The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6. Am J Physiol Regul Integr Comp Physiol 297(6):R1742–R1748